Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2026-03-27 Annual Report
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
Annual Report FY 2025
2026-03-27 English
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the quarter ended December 31, 2025. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 7,652 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. The document is primarily an announcement of financial results via a press release, not the full earnings release or interim report itself. Therefore, the best classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results, even though it is filed as an 8-K. The document is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, only referencing a press release. It is not a Regulatory Filing (RNS) because it is a standard 8-K current report announcing earnings. Hence, the classification is ER with high confidence.
2026-03-27 English
8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 24, 2026, by Werewolf Therapeutics, Inc. It announces that the company plans to explore strategic alternatives and has engaged a financial advisor for this purpose. The document includes a press release as an exhibit. There are no financial statements or detailed financial data included, nor is this a full report like an annual or quarterly report. The content is an announcement of a strategic evaluation and engagement of an advisor, which fits best under Capital/Financing Update (CAP) as it relates to strategic alternatives and financial advisory engagement. The document length is 3032 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2026-02-24 English
8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes a significant workforce reduction, departure and appointment of key officers, and updates on capital raising efforts. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Earnings Release or M&A filings. The primary focus is on management changes and operational updates. Therefore, the best classification is Board/Management Information (MANG). The document length (over 10,000 characters) supports it being a substantive report rather than a brief announcement or certification.
2026-02-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-11 English
8-K Filing
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 4, 2026, by Werewolf Therapeutics, Inc. The content focuses on a notice received from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. It details the deficiency notice, the compliance period, potential transfer to Nasdaq Capital Market, and possible delisting procedures. This is a regulatory announcement about the company's stock listing status, specifically a notice of potential delisting due to non-compliance with listing standards. The document is not a full financial report, earnings release, or management discussion, but an official notice about listing compliance and potential delisting. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is 5638 characters, which is sufficient to contain substantive information rather than just a brief announcement or report publication notice. Confidence is high given the clear focus on listing deficiency and delisting process.
2026-02-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.